Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model.
GU-BEN-FANG-XIAO decoction
IPA
chronic persistent asthma
iTRAQ
macrophage
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
10
2018
accepted:
08
04
2019
entrez:
29
5
2019
pubmed:
28
5
2019
medline:
28
5
2019
Statut:
epublish
Résumé
Gubenfangxiao decoction (GBFXD) is a traditional Chinese medicine based on a combination of Yu-Ping-Feng-San and Erchen decoctions. GBFXD has been widely used for decades in treating asthma at the Affiliated Hospital of Nanjing University of Chinese Medicine. Previously, GBFXD was found to reduce lung inflammation and airway remodeling; however, the underlying mechanism remains unknown. In this study, the effects of GBFXD on asthmatic mice were evaluated based on pathology and lung function; airway hyperresponsiveness (AHR) and pathology were compared among the two different mouse models utilized. Furthermore, the mechanism of action of GBFXD on asthmatic mice was analyzed using iTRAQ labeling technology combined with ingenuity pathway analysis (IPA). Modeling analysis of pre- and post-treatment proteins identified 75 differentially expressed proteins. These proteins were related to B-cell development, calcium-induced lymphocyte apoptosis, antigen presentation, and Th1 and Th2 activation pathways. Moreover, 68 differentially expressed proteins were identified in the GBFXD treatment group compared with the model group. Upstream regulatory factors predicted that interleukin (IL)-4 (necessary for inducing polarization of type 2 [M2] macrophages), cyclooxygenase, and prostaglandin E2 are significantly elevated in the model group. Based on IPA analysis, it was concluded that several pathways, including mitochondrial dysfunction and oxidative phosphorylation, are closely associated with the therapeutic effects of GBFXD in asthma. Moreover, the differential expression of several proteins, including the M2 markers, MRC1, ARG1, Retnla, Chil3, and CHIA, were validated by western blotting, confirming that GBFXD can reduce airway inflammation, which fits the pattern of an alternative M2 activation state, and attenuate AHR. Overall, our findings indicate that GBFXD significantly suppresses M2 macrophage polarization, providing further insights into the mechanism underlying the protective effects of GBFXD.
Identifiants
pubmed: 31133848
doi: 10.3389/fphar.2019.00441
pmc: PMC6514195
doi:
Types de publication
Journal Article
Langues
eng
Pagination
441Références
EMBO J. 2000 Aug 1;19(15):4046-55
pubmed: 10921885
J Virol. 2002 Jun;76(11):5654-66
pubmed: 11991994
Immunol Lett. 2003 Jan 22;85(2):173-80
pubmed: 12527225
Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44
pubmed: 15256389
J Allergy Clin Immunol. 2006 Jan;117(1):119-26
pubmed: 16387594
Blood. 2007 Sep 1;110(5):1578-86
pubmed: 17495130
N Engl J Med. 2007 Nov 15;357(20):2016-27
pubmed: 18003958
N Engl J Med. 2008 Apr 17;358(16):1682-91
pubmed: 18403759
J Immunol. 2008 Sep 1;181(5):3540-8
pubmed: 18714027
J Allergy Clin Immunol. 2009 Mar;123(3):596-602, 602.e1-8
pubmed: 19281908
Am J Respir Cell Mol Biol. 2010 May;42(5):595-603
pubmed: 19574533
J Proteome Res. 2009 Apr;8(4):1631-8
pubmed: 19714806
J Immunol. 2009 Oct 15;183(8):5379-87
pubmed: 19786549
J Agric Food Chem. 2009 Nov 11;57(21):10471-6
pubmed: 19831405
Am J Respir Crit Care Med. 2011 Feb 15;183(4):449-54
pubmed: 20851928
Pharmacotherapy. 2010 Nov;30(11):1109-16
pubmed: 20973684
J Allergy Clin Immunol. 2011 Mar;127(3):831-3
pubmed: 21167569
Ann Allergy Asthma Immunol. 2011 May;106(5):381-6
pubmed: 21530869
N Engl J Med. 2011 May 26;364(21):2006-15
pubmed: 21612469
Mol Biol Rep. 2012 Apr;39(4):4697-708
pubmed: 21947849
Annu Rev Immunol. 2013;31:317-43
pubmed: 23298208
Nature. 2013 Apr 25;496(7446):445-55
pubmed: 23619691
Allergy. 2013 Dec;68(12):1610-3
pubmed: 24117783
Mitochondrion. 2014 Jan;14(1):49-53
pubmed: 24270090
Nat Rev Immunol. 2014 Feb;14(2):81-93
pubmed: 24445666
PLoS One. 2014 Feb 06;9(2):e88362
pubmed: 24516640
Nat Rev Immunol. 2014 Oct;14(10):686-98
pubmed: 25234144
Pharmacogn Mag. 2015 Jul-Sep;11(43):546-54
pubmed: 26246730
Evid Based Complement Alternat Med. 2015;2015:501272
pubmed: 26504476
Am J Respir Crit Care Med. 2016 Mar 15;193(6):627-33
pubmed: 26540234
J Allergy Clin Immunol. 2016 Mar;137(3):700-9.e9
pubmed: 26560044
J Allergy Clin Immunol. 2016 Jul;138(1):130-141.e9
pubmed: 26915676
J Tradit Chin Med. 2016 Feb;36(1):32-8
pubmed: 26946616
J Tradit Chin Med. 2016 Feb;36(1):101-6
pubmed: 26946626
J Clin Cell Immunol. 2015 Dec;6(6):null
pubmed: 26962470
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
Pathog Dis. 2016 Jul;74(5):
pubmed: 27178560
J Allergy Clin Immunol. 2017 Jan;139(1):66-71.e3
pubmed: 27212083
J Clin Invest. 2016 Jul 1;126(7):2465-81
pubmed: 27214549
J Ethnopharmacol. 2016 Nov 4;192:496-509
pubmed: 27660012
J Allergy Clin Immunol. 2017 Jul;140(1):280-283.e3
pubmed: 28007476
Sci Rep. 2017 Jan 11;7:40318
pubmed: 28074863
Iran J Public Health. 2017 May;46(5):620-625
pubmed: 28560192
Lancet. 2017 Sep 2;390(10098):935-945
pubmed: 28797514
J Allergy Clin Immunol. 2017 Oct;140(4):895-906
pubmed: 28987219
Respir Med. 2017 Dec;133:16-21
pubmed: 29173444
Lancet. 2018 Feb 24;391(10122):783-800
pubmed: 29273246
Allergy Asthma Proc. 2018 May 1;39(3):15-29
pubmed: 29669661
Lancet Respir Med. 2018 Jul;6(7):e32
pubmed: 29976448
Front Pediatr. 2018 Jun 22;6:186
pubmed: 29988370
Minerva Pediatr. 2018 Oct;70(5):444-457
pubmed: 30035506
Front Pharmacol. 2018 Aug 06;9:841
pubmed: 30127739